用于COVID-19潜在治疗的临床试验中癌症药物重新利用的综述
A Review of Repurposed Cancer Drugs in Clinical Trials for Potential Treatment of COVID-19.
作者信息
Costa Bárbara, Vale Nuno
机构信息
OncoPharma Research Group, Center for Health Technology and Services Research (CINTESIS), Rua Dr. Plácido da Costa, 4200-450 Porto, Portugal.
Department of Community Medicine, Health Information and Decision (MEDCIDS), Faculty of Medicine, University of Porto, Al. Prof. Hernâni Monteiro, 4200-319 Porto, Portugal.
出版信息
Pharmaceutics. 2021 May 30;13(6):815. doi: 10.3390/pharmaceutics13060815.
The pandemic of the coronavirus disease 2019 (COVID-19) represents an unprecedented challenge to identify effective drugs for prevention and treatment. While the world's attention is focused on news of COVID-19 vaccine updates, clinical management still requires improvement. Due to the similarity of cancer-induced inflammation, immune dysfunction, and coagulopathy to COVID-19, anticancer drugs, such as Interferon, Pembrolizumab or Bicalutamide, are already being tested in clinical trials for repurposing, alone or in combination. Given the rapid pace of scientific discovery and clinical data generated by the large number of people rapidly infected, clinicians need effective medical treatments for this infection.
2019年冠状病毒病（COVID-19）大流行对确定有效的预防和治疗药物构成了前所未有的挑战。尽管全球注意力都集中在COVID-19疫苗更新的消息上，但临床管理仍有待改进。由于癌症引发的炎症、免疫功能障碍和凝血病与COVID-19有相似之处，一些抗癌药物，如干扰素、帕博利珠单抗或比卡鲁胺，已在临床试验中单独或联合进行重新利用测试。鉴于大量人群迅速感染所带来的科学发现和临床数据的快速积累，临床医生需要针对这种感染的有效医学治疗方法。
Zotero 插件